Skip to content

Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients post renal transplantation

Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients post renal transplantation - Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients post renal transplantation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033628
Enrollment
15
Registered
2018-08-06
Start date
2018-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients after kidney transplant

Interventions

Sponsors

Tokyo Women's Medical University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male and female aged 20 years or over, under 70 years old at the time of agreement acquisition 2. Patients diagnosed with diabetes 3. Patients who have undergone renal transplant 4. Patients with HbA1c (NGSP) of 6.0% or more and 9.0% or less Patients with Estimated Glomerular Filtration Rate (eGFR) of 30 mL / min / 1.73 m ^ 2 or more 5. Patients judged to have indications to use SGLT 2 inhibitors under normal medical treatment 6. Patients who have not used other SGLT2 inhibitors prior to the initiation of SGLT2 inhibitor prescription

Exclusion criteria

Exclusion criteria: 1. Patients with a history of hypersensitivity to components of SGLT2 inhibitors 2. Type 1 diabetes 3. Patients with postoperative ureteral stenosis such as ureteral stent placement 4. Patients with a history of repeated pyelonephritis 5. Patients with severe ketosis or diabetic coma 6. Patients with severe infections, before and after surgery, severe trauma 7. Patients with end-stage renal failure who are undergoing hemodialysis or peritoneal dialysis 8. Pregnant women or patients with potential pregnancy 9. Patients who research managers judged inappropriate as subjects

Design outcomes

Primary

MeasureTime frame
Change in HbA1c (NGSP value), glycoalbumin, blood glucose before and after treatment

Secondary

MeasureTime frame
1. Change before and after treatment of the following items; Urinary protein, urinary albumin and renal function (estimated glomerular filtration rate; eGFR) 2. Safety Event of the following side effects; Low blood sugar Urinary Tract Infections and Genital Infections Diabetic ketoacidosis Renal dysfunction Liver dysfunction fracture Malignant tumor Cardiac and cerebrovascular events Skin symptoms

Countries

Japan

Contacts

Public ContactNobue Tanaka

Tokyo Women's Medical University School of Medicine Diabetes Center

nobuetan.dmc@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026